Neuroprotection in glaucoma: current and emerging approaches

References

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in. 2010 and 2020. Br J Ophthalmol 2006;90(3):262-7
   PubMed Web of Science ®Google Scholar
• Quigley HA. Glaucoma. Lancet 2011;377(9774):1367-77
   PubMed Web of Science ®Google Scholar
• Kendell KR, Quigley HA, Kerrigan LA, et al. Primary open-angle glaucoma is not associated with photoreceptor loss. Invest Ophthalmol Vis Sci 1995;36(1):200-5
   Google Scholar
• Baltmr A, Duggan J, Nizari S, et al. Neuroprotection in glaucoma – is there a future role? Exp Eye Res 2010;91(5):554-66
   PubMed Web of Science ®Google Scholar
• Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res 1995;61(1):33-44
   PubMed Web of Science ®Google Scholar
• Dahlmann-Noor AH, Vijay S, Limb GA, Khaw PT. Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies. Drug Discov Today 2010;15(7-8):287-99
   Google Scholar
• Levin LA. Retinal ganglion cells and neuroprotection for glaucoma. Surv Ophthalmol 2003;48(Suppl 1):S21-4
   Google Scholar
• Goldberg I. Is this neuroprotective drug good for my glaucoma patients? Some key factors in clinical decision-making. Can J Ophthalmol 2007;42(3):418-20
   Google Scholar
• Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 2012;119(5):979-86
   PubMed Web of Science ®Google Scholar
• Quigley HA. Clinical trials for glaucoma neuroprotection are not impossible. Curr Opin Ophthalmol 2012;23(2):144-54
   PubMed Web of Science ®Google Scholar
• Levin LA. Extrapolation of animal models of optic nerve injury to clinical trial design. J Glaucoma 2004;13(1):1-5
   Google Scholar
• Knels L, Worm M, Wendel M, et al. Effects of advanced glycation end products-inductor glyoxal and hydrogen peroxide as oxidative stress factors on rat retinal organ cultures and neuroprotection by UK-14,304. J Neurochem 2008;106(4):1876-87
   Google Scholar
• Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 1999;9(Suppl 1):S17-21
   PubMed Web of Science ®Google Scholar
• WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42(12):2849-55
   PubMed Web of Science ®Google Scholar
• Donello JE, Padillo EU, Webster ML, et al. Alpha(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther 2001;296(1):216-23
   PubMed Web of Science ®Google Scholar
• Pinar-Sueiro S, Urcola H, Rivas MA, Vecino E. Prevention of retinal ganglion cell swelling by systemic brimonidine in a rat experimental glaucoma model. Clin Experiment Ophthalmol 2011;39(8):799-807
   PubMed Web of Science ®Google Scholar
• Araie M, Yamazaki Y, Sugiyama K, et al. [Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension – comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy]. Nihon Ganka Gakkai Zasshi 2012;116(10):955-66
   Google Scholar
• Joshi SR, Akat PB, Ramanand JB, et al. Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma. Indian J Ophthalmol 2013;61(12):765-7
   Google Scholar
• Moisseiev E, Kurtz S, Lazar M, Shemesh G. Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily. Clin Ophthalmol 2013;7:1269-73
   Google Scholar
• Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011;151(4):671-81
   PubMed Web of Science ®Google Scholar
• Pfeiffer N, Lamparter J, Gericke A, et al. Neuroprotection of medical IOP-lowering therapy. Cell Tissue Res 2013;353(2):245-51
   PubMed Web of Science ®Google Scholar
• Cordeiro MF, Levin LA. Clinical evidence for neuroprotection in glaucoma. Am J Ophthalmol 2011;152(5):715-16
   PubMed Web of Science ®Google Scholar
• Ammar DA, Hughes BA, Thompson DA. Neuropeptide Y and the retinal pigment epithelium: receptor subtypes, signaling, and bioelectrical responses. Invest Ophthalmol Vis Sci 1998;39(10):1870-8
   Google Scholar
• Santos-Carvalho A, Elvas F, Alvaro AR, et al. Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate. Cell Death Dis 2013;4:e636
   Google Scholar
• Alvaro AR, Martins J, Costa AC, et al. Neuropeptide Y protects retinal neural cells against cell death induced by ecstasy. Neuroscience 2008;152(1):97-105
   Google Scholar
• Alvaro AR, Rosmaninho-Salgado J, Ambrósio AF, Cavadas C. Neuropeptide Y inhibits [Ca2+]i changes in rat retinal neurons through NPY Y1, Y4, and Y5 receptors. J Neurochem 2009;109(5):1508-15
   Google Scholar
• D’Angelo I, Brecha NC. Y2 receptor expression and inhibition of voltage-dependent Ca2+ influx into rod bipolar cell terminals. Neuroscience 2004;125(4):1039-49
   Google Scholar
• Uckermann O, Wolf A, Kutzera F, et al. Glutamate release by neurons evokes a purinergic inhibitory mechanism of osmotic glial cell swelling in the rat retina: activation by neuropeptide Y. J Neurosci Res 2006;83(4):538-50
   PubMed Web of Science ®Google Scholar
• Blazynski C, Mosinger JL, Cohen AI. Comparison of adenosine uptake and endogenous adenosine-containing cells in mammalian retina. Vis Neurosci 1989;2(2):109-16
   Google Scholar
• Braas KM, Zarbin MA, Snyder SH. Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina. Proc Natl Acad Sci USA 1987;84(11):3906-10
   PubMed Web of Science ®Google Scholar
• Konno T, Uchibori T, Nagai A, et al. Effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on ocular blood flow in rabbits. Life Sci 2007;80(12):1115-22
   Google Scholar
• Kaelin-Lang A, Jurklies B, Niemeyer G. Effects of adenosinergic agents on the vascular resistance and on the optic nerve response in the perfused cat eye. Vision Res 1999;39(6):1059-68
   Google Scholar
• Polska E, Ehrlich P, Luksch A, et al. Effects of adenosine on intraocular pressure, optic nerve head blood flow, and choroidal blood flow in healthy humans. Invest Ophthalmol Vis Sci 2003;44(7):3110-14
   Google Scholar
• Li B, Rosenbaum PS, Jennings NM, et al. Differing roles of adenosine receptor subtypes in retinal ischemia-reperfusion injury in the rat. Exp Eye Res 1999;68(1):9-17
   PubMed Web of Science ®Google Scholar
• Larsen AK, Osborne NN. Involvement of adenosine in retinal ischemia. Studies on the rat. Invest Ophthalmol Vis Sci 1996;37(13):2603-11
   Google Scholar
• Hashimoto E, Kage K, Ogita T, et al. Adenosine as an endogenous mediator of hypoxia for induction of vascular endothelial growth factor mRNA in U-937 cells. Biochem Biophys Res Commun 1994;204(1):318-24
   PubMed Web of Science ®Google Scholar
• Zhong Y, Yang Z, Huang WC, Luo X. Adenosine, adenosine receptors and glaucoma: an updated overview. Biochim Biophys Acta 2013;1830(4):2882-90
   PubMed Web of Science ®Google Scholar
• Hartwick AT, Lalonde MR, Barnes S, Baldridge WH. Adenosine A1-receptor modulation of glutamate-induced calcium influx in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2004;45(10):3740-8
   Google Scholar
• Wu JH, Zhang SH, Gao FJ, et al. RNAi screening identifies GSK3beta as a regulator of DRP1 and the neuroprotection of lithium chloride against elevated pressure involved in downregulation of DRP1. Neurosci Lett 2013;554:99-104
   Google Scholar
• Park SW, Kim KY, Lindsey JD, et al. A selective inhibitor of drp1, mdivi-1, increases retinal ganglion cell survival in acute ischemic mouse retina. Invest Ophthalmol Vis Sci 2011;52(5):2837-43
   Google Scholar
• Chuang DM, Wang Z, Chiu CT. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 2011;4:15
   PubMed Web of Science ®Google Scholar
• Forlenza OV, de Paula VJ, Machado-Vieira R, et al. Does lithium prevent Alzheimer’s disease? Drugs Aging 2012;29(5):335-42
   PubMed Web of Science ®Google Scholar
• Jammoul F, Dégardin J, Pain D, et al. Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats. Mol Cell Neurosci 2010;43(4):414-21
   PubMed Web of Science ®Google Scholar
• Froger N, Jammoul F, Gaucher D, et al. Taurine is a crucial factor to preserve retinal ganglion cell survival. Adv Exp Med Biol 2013;775:69-83
   PubMed Web of Science ®Google Scholar
• Froger N, Cadetti L, Lorach H, et al. Taurine provides neuroprotection against retinal ganglion cell degeneration. PLoS One 2012;7(10):e42017
   Google Scholar
• Shao A, Hathcock JN. Risk assessment for the amino acids taurine, L-glutamine and L-arginine. Regul Toxicol Pharmacol 2008;50(3):376-99
   PubMed Web of Science ®Google Scholar
• Yamori Y, Liu L, Mizushima S, et al. Male cardiovascular mortality and dietary markers in 25 population samples of 16 countries. J Hypertens 2006;24(8):1499-505
   PubMed Web of Science ®Google Scholar
• Mey J, Thanos S. Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res 1993;602(2):304-17
   PubMed Web of Science ®Google Scholar
• Chen SD, Wang L, Zhang XL. Neuroprotection in glaucoma: present and future. Chin Med J (Engl) 2013;126(8):1567-77
   Web of Science ®Google Scholar
• Wilson AM, Di Polo A. Gene therapy for retinal ganglion cell neuroprotection in glaucoma. Gene Ther 2012;19(2):127-36
   Google Scholar
• Cheng L, Sapieha P, Kittlerova P, et al. TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo. J Neurosci 2002;22(10):3977-86
   PubMed Web of Science ®Google Scholar
• Harvey AR, Kamphuis W, Eggers R, et al. Intravitreal injection of adeno-associated viral vectors results in the transduction of different types of retinal neurons in neonatal and adult rats: a comparison with lentiviral vectors. Mol Cell Neurosci 2002;21(1):141-57
   Google Scholar
• Borras T. Advances in glaucoma treatment and management: gene therapy. Invest Ophthalmol Vis Sci 2012;53(5):2506-10
   Google Scholar
• Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2013;2:CD006539
   Google Scholar
• Johnson TV, Tomarev SI. Rodent models of glaucoma. Brain Res Bull 2010;81(2-3):349-58
   PubMed Web of Science ®Google Scholar
• Danias J, Shen F, Kavalarakis M, et al. Characterization of retinal damage in the episcleral vein cauterization rat glaucoma model. Exp Eye Res 2006;82(2):219-28
   Web of Science ®Google Scholar
• Levkovitch-Verbin H, Quigley HA, Martin KR, et al. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Invest Ophthalmol Vis Sci 2002;43(2):402-10
   PubMed Web of Science ®Google Scholar
• Sappington RM, Carlson BJ, Crish SD, Calkins DJ. The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. Invest Ophthalmol Vis Sci 2010;51(1):207-16
   PubMed Web of Science ®Google Scholar
• Chrysostomou V, Trounce IA, Crowston JG. Mechanisms of retinal ganglion cell injury in aging and glaucoma. Ophthalmic Res 2010;44(3):173-8
   Google Scholar
• Cone FE, Gelman SE, Son JL, et al. Differential susceptibility to experimental glaucoma among 3 mouse strains using bead and viscoelastic injection. Exp Eye Res 2010;91(3):415-24
   PubMedGoogle Scholar
• Cioffi GA, Wang L, Fortune B, et al. Chronic ischemia induces regional axonal damage in experimental primate optic neuropathy. Arch Ophthalmol 2004;122(10):1517-25
   Google Scholar
• Harada C, Namekata K, Guo X, et al. ASK1 deficiency attenuates neural cell death in GLAST-deficient mice, a model of normal tension glaucoma. Cell Death Differ 2010;17(11):1751-9
   PubMed Web of Science ®Google Scholar
• Liu Y, Pang IH. Challenges in the development of glaucoma neuroprotection therapy. Cell Tissue Res 2013;353(2):253-60
   Google Scholar
• Howell GR, Soto I, Ryan M, et al. Deficiency of complement component 5 ameliorates glaucoma in DBA/2J mice. J Neuroinflammation 2013;10(1):76
   Google Scholar
• Artes PH, Hutchison DM, Nicolela MT, et al. Threshold and variability properties of matrix frequency-doubling technology and standard automated perimetry in glaucoma. Invest Ophthalmol Vis Sci 2005;46(7):2451-7
   Google Scholar
• Heijl A, Bengtsson B, Hyman L, et al. Natural history of open-angle glaucoma. Ophthalmology 2009;116(12):2271-6
   PubMed Web of Science ®Google Scholar
• Caprioli J, Zeyen T. A critical discussion of the rates of progression and causes of optic nerve damage in glaucoma: international Glaucoma Think Tank II: July 25-26, 2008, Florence, Italy. J Glaucoma 2009;18(6 Suppl):S1-21
   Google Scholar
• Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114(11):1965-72
   PubMed Web of Science ®Google Scholar
• Araie M, Shirato S, Yamazaki Y, et al. Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: subgroup and subfield analyses of the nipradilol-timolol study. Jpn J Ophthalmol 2010;54(4):278-85
   Google Scholar
• Drance SM. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. J Glaucoma 1998;7(4):247-52
   PubMed Web of Science ®Google Scholar
• Koseki N, Araie M, Yamagami J, et al. Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. J Glaucoma 1999;8(2):117-23
   Google Scholar
• Sawada A, Kitazawa Y, Yamamoto T, et al. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. Ophthalmology 1996;103(2):283-8
   Google Scholar
• Garcia-Medina M, Garcia-Medina JJ, Garrido-Fernandez P, et al. Central corneal thickness, intraocular pressure, and degree of myopia in an adult myopic population aged 20 to 40 years in southeast Spain: determination and relationships. Clin Ophthalmol 2011;5:249-58
   Google Scholar
• Chen YJ, Tai MC, Cheng JH, et al. The longitudinal changes of the visual field in an Asian population with primary angle-closure glaucoma with and without an acute attack. J Ocul Pharmacol Ther 2012;28(5):529-35
   Google Scholar
• Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol 1982;100(1):135-46
   Google Scholar
• Chauhan BC, Garway-Heath DF, Goñi FJ, et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol 2008;92(4):569-73
   PubMed Web of Science ®Google Scholar
• Hoffmann EM, Miglior S, Zeyen T, et al. The Heidelberg retina tomograph ancillary study to the European glaucoma prevention study: study design and baseline factors. Acta Ophthalmol 2013;91(8):e612-19
   Google Scholar
• Goren D, Demirel S, Fortune B, Gardiner SK. Correlating Perimetric Indices With Three Nerve Fiber Layer Thickness Measures. Optom Vis Sci 2013;90(12):1353-60
   Google Scholar
• Rao HL, Addepalli UK, Chaudhary S, et al. Ability of different scanning protocols of spectral domain optical coherence tomography to diagnose preperimetric glaucoma. Invest Ophthalmol Vis Sci 2013;54(12):7252-7
   Google Scholar
• Lisboa R, Weinreb RN, Medeiros FA. Combining structure and function to evaluate glaucomatous progression: implications for the design of clinical trials. Curr Opin Pharmacol 2013;13(1):115-22
   Google Scholar
• Harwerth RS, Wheat JL, Fredette MJ, Anderson DR. Linking structure and function in glaucoma. Prog Retin Eye Res 2010;29(4):249-71
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Lisboa R, Weinreb RN, et al. A combined index of structure and function for staging glaucomatous damage. Arch Ophthalmol 2012;130(9):1107-16
   Google Scholar
• Weinreb RN, Kaufman PL. Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function. Invest Ophthalmol Vis Sci 2011;52(11):7842-51
   PubMed Web of Science ®Google Scholar
• Cordeiro MF, Guo L, Luonget V, et al. Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci USA 2004;101(36):13352-6
   PubMed Web of Science ®Google Scholar
• Tilley BC, Palesch YY, Kieburtz K, et al. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 2006;66(5):628-33
   Google Scholar
• NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66(5):664-71
   Google Scholar
• Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson’s disease. Mov Disord 2013;28(1):86-95
   PubMed Web of Science ®Google Scholar
• Padmanabhan SK, Berry S, Dragalin V, Krams M. A bayesian dose-finding design adapting to efficacy and tolerability response. J Biopharm Stat 2012;22(2):276-93
   PubMed Web of Science ®Google Scholar
• Wang SJ, Hung HM, O’Neill R. Adaptive design clinical trials and trial logistics models in CNS drug development. Eur Neuropsychopharmacol 2011;21(2):159-66
   PubMed Web of Science ®Google Scholar
• Meurer WJ, Barsan WG. Spinal Cord Injury Neuroprotection and the Promise of Flexible Adaptive Clinical Trials. World Neurosurg 2013. [Epub ahead of print]
   Google Scholar
• Mi MY, Betensky RA. An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials. Clin Trials 2013;10(2):207-15
   PubMed Web of Science ®Google Scholar
• Broberg P. Sample size re-assessment leading to a raised sample size does not inflate type I error rate under mild conditions. BMC Med Res Methodol 2013;13:94
   Google Scholar
• Committee for medicinal products for human use (CHMP). Reflection Paper on methodological issues in confirmatory trials planned with an adaptive design. European Medicines Agency; London, UK: 2007
   Google Scholar
• Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86(1):97-100
   PubMed Web of Science ®Google Scholar
• Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. Jama 2011;306(23):2608-9
   PubMed Web of Science ®Google Scholar
• Wang SJ, Hung HM, O’Neill R. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program. J Biopharm Stat 2011;21(4):846-59
   PubMed Web of Science ®Google Scholar
• Berry SM, Spinelli W, Littman GS, et al. A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug. Clin Trials 2010;7(2):121-35
   Google Scholar
• Elkind MS, Sacco RL, MacArthur RB, et al. The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke 2008;3(3):210-18
   Google Scholar
• Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 1996;10(Suppl 1):31-5
   PubMed Web of Science ®Google Scholar
• Cummings J, Gould H, Zhong K. Advances in designs for Alzheimer’s disease clinical trials. Am J Neurodegener Dis 2012;1(3):205-16
   PubMedGoogle Scholar
• Olanow CW, Rascol O, Hauser R, et al. ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• Schapira AH, Albrecht S, Barone P, et al. Rationale for delayed-start study of pramipexole in Parkinson’s disease: the PROUD study. Mov Disord 2010;25(11):1627-32
   Google Scholar
• Zhang RY, Leon AC, Chuang-Stein C, Romano SJ. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease. Clin Trials 2011;8(1):5-14
   Google Scholar
• Shimazawa M, Nakajima Y, Mashima Y, Hara H. Docosahexaenoic acid (DHA) has neuroprotective effects against oxidative stress in retinal ganglion cells. Brain Res 2009;1251:269-75
   PubMed Web of Science ®Google Scholar
• Schnebelen C, Pasquis B, Salinas-Navarro M, et al. A dietary combination of omega-3 and omega-6 polyunsaturated fatty acids is more efficient than single supplementations in the prevention of retinal damage induced by elevation of intraocular pressure in rats. Graefes Arch Clin Exp Ophthalmol 2009;247(9):1191-203
   Google Scholar
• Juravleva E, Barbakadze T, Mikeladze D, Kekelidze T. Creatine enhances survival of glutamate-treated neuronal/glial cells, modulates Ras/NF-kappaB signaling, and increases the generation of reactive oxygen species. J Neurosci Res 2005;79(1-2):224-30
   PubMed Web of Science ®Google Scholar
• Siu AW, Ortiz GG, Benitez-King G, et al. Effects of melatonin on the nitric oxide treated retina. Br J Ophthalmol 2004;88(8):1078-81
   PubMed Web of Science ®Google Scholar
• Tang Q, Hu Y, Cao Y. Neuroprotective effect of melatonin on retinal ganglion cells in rats. J Huazhong Univ Sci Technolog Med Sci 2006;26(2):235-7, 253
   Google Scholar
• Cazevieille C, Osborne NN. Retinal neurones containing kainate receptors are influenced by exogenous kainate and ischaemia while neurones lacking these receptors are not -- melatonin counteracts the effects of ischaemia and kainate. Brain Res 1997;755(1):91-100
   Google Scholar
• Thiagarajan G, Chandani S, Harinarayana Rao S, et al. Molecular and cellular assessment of ginkgo biloba extract as a possible ophthalmic drug. Exp Eye Res 2002;75(4):421-30
   Google Scholar
• Hirooka K, Tokuda M, Miyamoto O, et al. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr Eye Res 2004;28(3):153-7
   PubMed Web of Science ®Google Scholar
• Chung HS, Harris A, Kristinsson JK, et al. Ginkgo biloba extract increases ocular blood flow velocity. J Ocul Pharmacol Ther 1999;15(3):233-40
   PubMedGoogle Scholar
• Eckert A, Keil U, Scherping I, et al. Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract EGb 761. Ann N Y Acad Sci 2005;1056:474-85
   PubMed Web of Science ®Google Scholar
• Aydemir O, Nazıroğlu M, Celebi S, et al. Antioxidant effects of alpha-, gamma- and succinate-tocopherols in guinea pig retina during ischemia-reperfusion injury. Pathophysiology 2004;11(3):167-71
   Google Scholar
• Nakajima Y, Inokuchi Y, Nishi M, et al. Coenzyme Q10 protects retinal cells against oxidative stress in vitro and in vivo. Brain Res 2008;1226:226-33
   PubMed Web of Science ®Google Scholar
• Nucci C, Tartaglione R, Cerulli A, et al. Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. Int Rev Neurobiol 2007;82:397-406
   PubMed Web of Science ®Google Scholar
• Lee D, Kim KY, Shim MS, et al. Coenzyme Q10 ameliorates oxidative stress and prevents mitochondrial alteration in ischemic retinal injury. Apoptosis 2013. [Epub ahead of print]
   Google Scholar
• Zhang B, Safa R, Rusciano D, Osborne NN. Epigallocatechin gallate, an active ingredient from green tea, attenuates damaging influences to the retina caused by ischemia/reperfusion. Brain Res 2007;1159:40-53
   PubMed Web of Science ®Google Scholar
• Yang SW, Lee BR, Koh JW. Protective effects of epigallocatechin gallate after UV irradiation in cultured human retinal pigment epithelial cells. Korean J Ophthalmol 2007;21(4):232-7
   Google Scholar
• Sattler MB, Merkler D, Maier K, et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004;11(Suppl 2):S181-92
   PubMedGoogle Scholar
• Kilic U, Kilic E, Soliz J, et al. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J 2005;19(2):249-51
   Google Scholar
• Bakalash S, Kessler A, Mizrahi T, et al. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Ophthalmol Vis Sci 2003;44(8):3374-81
   Google Scholar
• Ben Simon GJ, Bakalash S, Aloni E, Rosner M. A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy. Am J Ophthalmol 2006;141(6):1105-11
   Google Scholar
• Li X, Qian S.H, Sun XH. [Protection of autoimmunity induced by copolymer-1 on optic nerve: experiment with rat glaucoma models]. Zhonghua Yi Xue Za Zhi 2008;88(30):2152-4
   Google Scholar
• Laengle UW, Trendelenburg AU, Markstein R, et al. GLC756 decreases TNF-alpha via an alpha2 and beta2 adrenoceptor related mechanism. Exp Eye Res 2006;83(5):1246-51
   Google Scholar
• Laengle UW, Markstein R, Pralet D, et al. Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-alpha release in vitro from activated rat mast cells. Exp Eye Res 2006;83(6):1335-9
   Google Scholar
• Ishii Y, Kwong JM, Caprioli J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003;44(5):1982-92
   Google Scholar
• Caprioli J, Ishii Y, Kwong JM. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Trans Am Ophthalmol Soc 2003;101:39-50; discussion 50-1
   PubMedGoogle Scholar
• Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 2006;97(6):1611-26
   PubMed Web of Science ®Google Scholar
• WoldeMussie E, Yoles E, Schwartz M, et al. Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma 2002;11(6):474-80
   PubMed Web of Science ®Google Scholar
• Yucel YH, Gupta N, Zhang Q, et al. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol 2006;124(2):217-25
   Google Scholar
• Hare WA, Gupta N, Zhang Q, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: functional measures. Invest Ophthalmol Vis Sci 2004;45(8):2625-39
   Google Scholar
• Guo L, Salt TE, Maass A, et al. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest Ophthalmol Vis Sci 2006;47(2):626-33
   PubMed Web of Science ®Google Scholar
• Tsuda K. Neuroprotective effects of MK-801 and catecholamine release in the central nervous system. Stroke 2004;35(5):e96
   Google Scholar
• Chaudhary P, Ahmed F, Sharma SC. MK801-a neuroprotectant in rat hypertensive eyes. Brain Res 1998;792(1):154-8
   PubMed Web of Science ®Google Scholar
• Otori Y, Wei JY, Barnstable CJ. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci 1998;39(6):972-81
   Google Scholar
• Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 2007;104(33):13444-9
   PubMed Web of Science ®Google Scholar
• Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994;91(25):12243-7
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Yoneda S, Hara H. Neuroprotective effects of beta-secretase inhibitors against rat retinal ganglion cell death. Neurosci Lett 2004;370(1):61-4
   Google Scholar
• Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures. Invest Ophthalmol Vis Sci 2004;45(8):2640-51
   Google Scholar
• Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 2002;958(1):210-21
   PubMed Web of Science ®Google Scholar
• Zwart I, Hill AJ, Al-Allaf F, et al. Umbilical cord blood mesenchymal stromal cells are neuroprotective and promote regeneration in a rat optic tract model. Exp Neurol 2009;216(2):439-48
   PubMed Web of Science ®Google Scholar
• Hu Y, Tan HB, Wang XM, et al. Bone marrow mesenchymal stem cells protect against retinal ganglion cell loss in aged rats with glaucoma. Clin Interv Aging 2013;8:1467-70
   Web of Science ®Google Scholar
• Johnson TV, Bull ND, Hunt DP, et al. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest Ophthalmol Vis Sci 2010;51(4):2051-9
   PubMed Web of Science ®Google Scholar
• Voulgari-Kokota A, Fairless R, Karamita M, et al. Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function. Exp Neurol 2012;236(1):161-70
   Google Scholar
• Bull ND, Limb GA, Martin KR. Human Muller stem cell (MIO-M1) transplantation in a rat model of glaucoma: survival, differentiation, and integration. Invest Ophthalmol Vis Sci 2008;49(8):3449-56
   Google Scholar
• Song WT, Zhang XY, Xia XB. Atoh7 promotes the differentiation of retinal stem cells derived from Muller cells into retinal ganglion cells by inhibiting Notch signaling. Stem Cell Res Ther 2013;4(4):94
   PubMedGoogle Scholar
• Aoki H, Hara A, Niwa M, et al. Transplantation of cells from eye-like structures differentiated from embryonic stem cells in vitro and in vivo regeneration of retinal ganglion-like cells. Graefes Arch Clin Exp Ophthalmol 2008;246(2):255-65
   Google Scholar
• Crigler L, Robey RC, Asawachaicharn A, et al. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 2006;198(1):54-64
   PubMed Web of Science ®Google Scholar
• Johnson TV, Dekorver NW, Levasseur VA, et al. Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome. Brain 2013;137(Pt 2):503-19
   Google Scholar
• Harper MM, Grozdanic SD, Blits B, et al. Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes. Invest Ophthalmol Vis Sci 2011;52(7):4506-15
   Google Scholar
• Hambright D, Park KY, Brooks M, et al. Long-term survival and differentiation of retinal neurons derived from human embryonic stem cell lines in un-immunosuppressed mouse retina. Mol Vis 2012;18:920-36
   PubMed Web of Science ®Google Scholar
• Park HY, Kim JH, Sun Kim H, Park CK. Stem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina. Brain Res 2012;1469:10-23
   PubMed Web of Science ®Google Scholar
• Manuguerra-Gagne R, Boulos PR, Ammar A, et al. Transplantation of mesenchymal stem cells promotes tissue regeneration in a glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment. Stem Cells 2013;31(6):1136-48
   PubMed Web of Science ®Google Scholar
• Li N, Li XR, Yuan JQ. Effects of bone-marrow mesenchymal stem cells transplanted into vitreous cavity of rat injured by ischemia/reperfusion. Graefes Arch Clin Exp Ophthalmol 2009;247(4):503-14
   Google Scholar
• Yu S, Tanabe T, Dezawa M, et al. Effects of bone marrow stromal cell injection in an experimental glaucoma model. Biochem Biophys Res Commun 2006;344(4):1071-9
   PubMedGoogle Scholar
• Zhou X, Xia XB, Xiong SQ. Neuro-protection of retinal stem cells transplantation combined with copolymer-1 immunization in a rat model of glaucoma. Mol Cell Neurosci 2013;54:1-8
   Google Scholar
• Zhao T, Li Y, Tang L, et al. Protective effects of human umbilical cord blood stem cell intravitreal transplantation against optic nerve injury in rats. Graefes Arch Clin Exp Ophthalmol 2011;249(7):1021-8
   PubMedGoogle Scholar
• Mead B, Logan A, Berry M, et al. Intravitreally transplanted dental pulp stem cells promote neuroprotection and axon regeneration of retinal ganglion cells after optic nerve injury. Invest Ophthalmol Vis Sci 2013;54(12):7544-56
   PubMed Web of Science ®Google Scholar
• Hellstrom M, Pollett MA, Harvey AR. Post-injury delivery of rAAV2-CNTF combined with short-term pharmacotherapy is neuroprotective and promotes extensive axonal regeneration after optic nerve trauma. J Neurotrauma 2011;28(12):2475-83
   Google Scholar
• Di Polo A, Aigner LJ, Dunn RJ, et al. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc Natl Acad Sci USA 1998;95(7):3978-83
   PubMed Web of Science ®Google Scholar
• Isenmann S, Klöcker N, Gravel C, Bähr M. Short communication: protection of axotomized retinal ganglion cells by adenovirally delivered BDNF in vivo. Eur J Neurosci 1998;10(8):2751-6
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Ikeda Y, Yonemitsu Y, et al. Pigment epithelium-derived factor gene therapy targeting retinal ganglion cell injuries: neuroprotection against loss of function in two animal models. Hum Gene Ther 2011;22(5):559-65
   PubMed Web of Science ®Google Scholar
• Leaver SG, Cui Q, Plant GW, et al. AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells. Gene Ther 2006;13(18):1328-41
   PubMed Web of Science ®Google Scholar
• Mo X, Yokoyama A, Oshitari T, et al. Rescue of axotomized retinal ganglion cells by BDNF gene electroporation in adult rats. Invest Ophthalmol Vis Sci 2002;43(7):2401-5
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Takano M, Matsumoto N, et al. Effect of GDNF gene transfer into axotomized retinal ganglion cells using in vivo electroporation with a contact lens-type electrode. Gene Ther 2005;12(4):289-98
   Google Scholar
• Bonfanti L, Strettoi E, Chierzi S, et al. Protection of retinal ganglion cells from natural and axotomy-induced cell death in neonatal transgenic mice overexpressing bcl-2. J Neurosci 1996;16(13):4186-94
   Google Scholar
• Malik JM, Shevtsova Z, Bähr M, Kügler S. Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol Ther 2005;11(3):373-81
   PubMed Web of Science ®Google Scholar
• Lingor P, Koeberle P, Kügler S, Bähr M. Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo. Brain 2005;128(Pt 3):550-8
   Google Scholar
• Ju WK, Kim K-Y, Duong-Polk KX, et al. Increased optic atrophy type 1 expression protects retinal ganglion cells in a mouse model of glaucoma. Mol Vis 2010;16:1331-42
   PubMedGoogle Scholar
• McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 2002;43(4):1077-87
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Kalinski H, Berry M, et al. Ocular neuroprotection by siRNA targeting caspase-2. Cell Death Dis 2011;2:e173
   Google Scholar
• Koeberle PD, Wang Y, Schlichter LC. Kv1.1 and Kv1.3 channels contribute to the degeneration of retinal ganglion cells after optic nerve transection in vivo. Cell Death Differ 2010;17(1):134-44
   Google Scholar
• Hegazy KA, Dunn MW, Sharma SC. Functional human heme oxygenase has a neuroprotective effect on adult rat ganglion cells after pressure-induced ischemia. Neuroreport 2000;11(6):1185-9
   Google Scholar
• Fischer D, Petkova V, Thanos S, Benowitz LI. Switching mature retinal ganglion cells to a robust growth state in vivo: gene expression and synergy with RhoA inactivation. J Neurosci 2004;24(40):8726-40
   Google Scholar
• Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(5):481-8
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheung YK, Levin B, et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 2008;9(4):212-22
   PubMed Web of Science ®Google Scholar
• Knafl GJ, Schoenthaler A, Ogedegbe G. Secondary analysis of electronically monitored medication adherence data for a cohort of hypertensive African-Americans. Patient Prefer Adherence 2012;6:207-19
   Web of Science ®Google Scholar
• Elkind MS, Sacco RL, Macarthur RB, et al. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis 2009;28(3):266-75
   Google Scholar
• Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12(8):756-67
   PubMed Web of Science ®Google Scholar
• Lewis RJ, Viele K, Broglio K, et al. An adaptive, phase II, dose-finding clinical trial design to evaluate L-carnitine in the treatment of septic shock based on efficacy and predictive probability of subsequent phase III success. Crit Care Med 2013;41(7):1674-8
   Google Scholar
• Geiger MJ, Skrivanek Z, Gaydos B, et al. An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics. J Diabetes Sci Technol 2012;6(6):1319-27
   Google Scholar
• Stephenson JJ, Nemunaitis J, Joy AA, et al. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung Cancer 2014;83(2):219-23
   PubMed Web of Science ®Google Scholar
• Bleck T, Cock H, Chamberlain J, et al. The established status epilepticus trial 2013. Epilepsia 2013;54(Suppl 6):89-92
   PubMed Web of Science ®Google Scholar
• Lee SM, Hackshaw A. A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial. Cancer Med 2013;2(3):360-6
   Google Scholar
• Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009;66(2):235-44
   PubMed Web of Science ®Google Scholar
• Ginsberg MD, Palesch YY, Hill MD, et al. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol 2013;12(11):1049-58
   PubMed Web of Science ®Google Scholar
• Lewis RA, McDermott MP, Herrmann DN, et al. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 2013;70(8):981-7
   PubMed Web of Science ®Google Scholar